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The ultimate goal of genome-wide association (GWA) studies is to identify genetic variants contributing effects to complex
phenotypes in order to improve our understanding of the biological architecture underlying the trait. One approach to
allow us to meet this challenge is to consider more refined sub-phenotypes of disease, defined by pattern of symptoms, for
example, which may be physiologically distinct, and thus may have different underlying genetic causes. The disadvantage
of sub-phenotype analysis is that large disease cohorts are sub-divided into smaller case categories, thus reducing power to
detect association. To address this issue, we have developed a novel test of association within a multinomial regression
modeling framework, allowing for heterogeneity of genetic effects between sub-phenotypes. The modeling framework is
extremely flexible, and can be generalized to any number of distinct sub-phenotypes. Simulations demonstrate the power of
the multinomial regression-based analysis over existing methods when genetic effects differ between sub-phenotypes, with
minimal loss of power when these effects are homogenous for the unified phenotype. Application of the multinomial
regression analysis to a genome-wide association study of type 2 diabetes, with cases categorized according to body mass
index, highlights previously recognized differential mechanisms underlying obese and non-obese forms of the disease, and
provides evidence of a potential novel association that warrants follow-up in independent replication cohorts. Genet.
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Key words: multinomial regression; sub-phenotype analysis; genome-wide association study; type 2 diabetes; obesity
Contract grant sponsor: Wellcome Trust; Contract grant number: 076113; Contract grant sponsor: Wellcome Trust; Contract grant number:
WT081682/Z/06/Z.
Correspondence to: Andrew P. Morris, Genetic and Genomic Epidemiology Unit, The Wellcome Trust Centre for Human Genetics, The
Henry Wellcome Building, Roosevelt Drive, Oxford OX3 7BN, United Kingdom. E-mail: amorris@well.ox.ac.uk
Received 27 July 2009; Revised 8 October 2009; Accepted 10 November 2009
Published online 28 December 2009 in Wiley InterScience (www.interscience.wiley.com).
DOI: 10.1002/gepi.20486
INTRODUCTION
Genome-wide association (GWA) studies, such as those
undertaken by the Wellcome Trust Case Control Con-
sortium (WTCCC) [The Wellcome Trust Case Control
Consortium, 2007], have proved to be extremely successful
in identifying novel genetic components underlying
complex human disease. Much of this success is due to
better understanding of common human genetic variation
[The International HapMap Consortium, 2007], improve-
ments in the throughput and cost-efficiency of genome-
wide genotyping platforms, and the availability of large,
well characterized, population-based cohorts that provide
sufficient power to detect the modest effects we expect for
complex traits. Large international consortia are now
undertaking collaborative meta-analyses of the results of
GWA studies across populations with common ancestry,
utilizing effective sample sizes of tens of thousands of
individuals for discovery and replication of increasingly
modest genetic effects contributing to traits such as type 2
diabetes (T2D) [Zeggini et al., 2008], Crohn’s disease (CD)
[Barrett et al., 2008], obesity [Willer et al., 2009], rheumatoid
arthritis [Raychaudhuri et al., 2008], and schizophrenia
[O’Donovan et al., 2008]. However, despite these successes,
much of the genetic contributions to these, and other
complex traits, remain unexplained.
One approach to advance our understanding of the
biological mechanisms underlying a phenotype under in-
vestigation is to refine the trait, somehow. These sub-
phenotypes could be defined by severity of disease, age of
o n s e t ,o rt h es i t ea n d / o rp a t t e r no fs y m p t o m s ,s u c ha sw es e e
in inflammatory bowel disease, for example. By doing this, we
may detect associations with variants contributing different
effects to sub-phenotypes that would otherwise be overlooked
by considering all cases, simultaneously, as the same
phenotype. However, by focusing on specific sub-phenotypes,
r 2009 Wiley-Liss, Inc.we reduce sample size, and thus will lose power to map loci
contributing homogeneous effects to the unified phenotype.
In order to address this issue, we have developed a novel
test for disease association, allowing for heterogeneity in
genetic effects between sub-phenotypes, within a multi-
nomial regression framework. We demonstrate, by simula-
tion, that the multinomial regression approach has greater
power to detect disease association, in the presence of
heterogeneity in allelic odds ratios between sub-pheno-
types, than do existing methods formulated in a logistic
regression framework. Furthermore, when genetic effects
are consistent across sub-phenotypes, the loss in power of
the multinomial regression analysis is minimal, despite the
additional parameters required in the model.
To demonstrate the utility of our multinomial regression
approach, we have re-analyzed a GWA study of T2D from
the main WTCCC experiment [The Wellcome Trust Case
Control Consortium, 2007] by categorizing cases according
to obesity, a well established risk factor for the disease,
typically assessed by body mass index (BMI). The clear
relationship between T2D and obesity would suggest that
variants associated with BMI may also influence suscept-
ibility to the disease. For example, analysis of the main
WTCCC experiment highlighted strong evidence of
association of T2D with variants in FTO (trend test
P55.2 10
 8). However, analysis of BMI as a continuous
trait in the aforementioned case samples demonstrated
strong evidence of obesity association with precisely the
same variants (trend test P58.0 10
 6). In particular,
high-risk alleles for T2D were also associated with
increased BMI [Frayling et al., 2007]. Our multinomial
regression analysis of the GWA study, allowing for
heterogeneity of genetic effects between obese and non-
obese cases, provides stronger signals of association at
several of the now established T2D loci than do conven-
tional logistic regression-based methods applied to all
cases combined. Our results confirm previous findings of
heterogeneity in genetic effects according to obesity sub-
phenotype at variants in FTO and TCF7L2 [Cauchi et al.,
2006, 2008; Freathy et al., 2008; Timpson et al., 2009], and
highlight a potential novel T2D association that warrants
follow-up in replication cohorts.
MODEL AND METHODS
MODEL FORMULATION AND ANALYSIS
FRAMEWORK
Consider a case-control sample of unrelated individuals,
where cases are categorized according to K possible
disjoint sub-phenotypes. We denote the phenotype of the
ith individual by yi, where yi50 for controls, and yi5k for
cases with the kth sub-phenotype. Under the assumption
of a linear trend in the allelic odds ratio (i.e. multiplicative
disease risks), we can model the log-odds of the kth sub-
phenotype for the ith individual in a multinomial
regression framework, given by
ln
Pðyi ¼ kÞ
Pðyi ¼ 0Þ
  
¼ ak1lkGi1bkxi: ð1Þ
In this expression, Gi denotes the SNP genotype of the ith
individual, coded as 0, 1, or 2, according to the number of
minor alleles they carry. Furthermore, xi denotes a vector
of their covariate measurements, with corresponding
regression coefficients bk. The parameter lk represents
the allelic log-odds ratio for the minor allele, relative to the
major allele, for the kth sub-phenotype.
Within a multinomial regression framework, the log-
likelihood contribution of the ith individual is given by
lnfðyijGi;xi;a;k;bÞ¼
X K
k¼1
Iðyi ¼ kÞln
Pðyi ¼ kÞ
Pðyi ¼ 0Þ
  
  ln 11
X K
k¼1
Pðyi ¼ kÞ
Pðyi ¼ 0Þ
"#
;
where I(yi5k) is an indicator variable, taking the value 1 if
they have the kth sub-phenotype, and 0 otherwise. We can
then construct a likelihood ratio test of association of the
SNP with disease, allowing for heterogeneity of allelic
odds ratios between sub-phenotypes, by comparing the
deviance of a model in which lk50 for all sub-phenotypes
to that in which lk is unconstrained, given by
L ¼2lnfðyijGi;xi;a;k;bÞ
  2lnfðyijGi;xi;a;k ¼ 0;bÞ:
Under the null hypothesis of no association between the
disease and SNP, L has an approximate w
2 distribution
with K degrees of freedom.
Within a multinomial regression framework, we can also
construct a test of heterogeneity of allelic odds ratios at the
SNP between sub-phenotypes by comparing the deviance
of a model in which lk5y for all sub-phenotypes to that in
which lk is unconstrained, given by
LHET ¼2lnfðyijGi;xi;a;k;bÞ
  2lnfðyijGi;xi;a;k ¼ h;bÞ:
Under the null hypothesis of no heterogeneity of allelic odds
ratios at the SNP between sub-phenotypes, LHET has an
approximate w
2 distribution with K-1 degrees of freedom.
The multinomial logistic regression framework de-
scribed above is extremely flexible and can be easily
extended to allow for non-multiplicative disease risks, for
example, by including an additional indicator I(Gi51) of
dominance in equation (1). Furthermore, we can test for
association with imputed genotype data within this
framework by replacing Gi in equation (1) with the
expected genotype from the posterior distribution of calls
[Marchini et al., 2007]. The multinomial regression model
can be fitted using the mlogit function in R [R Develop-
ment Core Team, 2009].
SIMULATION STUDY
We have performed simulations to investigate the power
of the multinomial regression framework to test for disease
association and heterogeneity in allelic odds ratios
between sub-phenotypes, and to compare its performance
to existing logistic regression-based approaches. We
considered a disease for which cases are categorized
according to two sub-phenotypes, and examined a wide
range of association scenarios, parameterized in terms of:
(i) the minor allele frequency (MAF) of the causal SNP;
and (ii) the heterozygous log-relative risk, under a multi-
plicative disease model, for each sub-phenotype.
For each scenario, we simulated 10,000 replicates of
data, each consisting of causal SNP genotype data under
the assumption of Hardy–Weinberg equilibrium (HWE)
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cases of sub-phenotype 2. For each replicate of data, we
performed the following tests of association and hetero-
geneity, and recorded the P-value for each.
1. MULTINOMIAL: test of association of the causal SNP
with disease, allowing heterogeneity of allelic odds
ratios between sub-phenotypes, within a multinomial
regression framework (2,000 cases against 2,000
controls).
2. LOGISTIC: test of association of the causal SNP with
disease, assuming the genetic effect to be the same
for both sub-phenotypes, within a logistic regression
framework (2,000 cases against 2,000 controls).
3. SP1 and SP2: tests of association of the causal SNP
with each sub-phenotype, separately, within a
logistic regression framework (1,000 cases each
against 2,000 shared controls).
4. HETEROGENEITY: test of heterogeneity of the effect
of the causal SNP between sub-phenotypes within a
multinomial regression framework (2,000 cases
against 2,000 controls).
5. SP1vSP2: test of heterogeneity of the effect of the
causal SNP between sub-phenotypes within a
logistic regression framework (1,000 cases of sub-
phenotype 1 against 1,000 cases of sub-phenotype 2).
For each test, we estimate power by the proportion
of replicates for which the P-value meets a nominal
significance threshold of 5%.
APPLICATION TO A GWA STUDY OF T2D
OBESITY SUB-PHENOTYPES
The T2D component of the main WTCCC experiment [The
Wellcome Trust Case Control Consortium, 2007] consists of
1,999 cases from the Diabetes UK Warren 2 repository, and
3,004 controls from the 1958 British Birth Cohort (58C) and
the UK National Blood Service (NBS). All samples were
genotyped using the Affymetrix GeneChip 500K Mapping
Array Set that incorporates 500,568 SNPs, genome-wide. We
utilized exactly the same quality control (QC) filters
employed by the WTCCC to exclude samples and SNPs, full
details of which are presented in the description of the main
experiment [The Wellcome Trust Case Control Consortium,
2007]. Briefly, case and control samples were excluded on the
basis of call rate, outlying genome-wide heterozygosity,
discrepancies in WTCCC and external identifying informa-
tion, non-Caucasian ancestry, duplication and apparent
relatedness. SNPs were excluded on the basis of call rate,
extreme deviation from HWE, differential allele and/or
genotype frequencies between the 58C and NBS control
cohorts, or manual visual inspection of genotype calls.
For our analysis, each T2D case was assigned to one of
two obesity sub-phenotypes: non-obese (BMI r30kgm
 2)
and obese (BMI >30kgm
 2). Cases passing QC filters, but
with unknown BMI, were unclassified and hence excluded
from the analysis. For each SNP passing QC filters, the
following tests were performed:
1. disease association within a multinomial regression
framework (i.e. controls against obese and non-obese
T2D sub-phenotypes);
2. disease association within a logistic regression
framework (i.e. controls against obese and non-obese
T2D cases combined);
3. heterogeneity of effects between obesity sub-pheno-
types within a multinomial regression framework.
RESULTS
SIMULATION STUDY
Table I presents a summary of false-positive error rates,
at a nominal significance level of 5%, of each multinomial
or logistic regression-based test of association or hetero-
geneity. Estimates are based on 10,000 replicates of data
generated under the null hypothesis of no association of
the SNP with either phenotype, and are entirely consistent
with the nominal significance level.
Figures 1–3 present the power, at a nominal significance
level of 5%, of each multinomial or logistic regression-based
test of association or heterogeneity, as a function of the
heterozygote log-relative risk of disease for sub-phenotype 1.
Results are presented for a causal variant with 10% MAF in
three distinct settings: (i) the effect of the causal variant is the
same for both sub-phenotypes (Fig. 1); (ii) the causal SNP has
TABLE I. False-positive error rates of tests of disease association and heterogeneity of genetic effects between two sub-
phenotypes at a nominal 5% significance level
Test Framework Sample size False-positive error rate % (standard error)
MULTINOMIAL Multinomial 2,000 cases v 2,000 controls 4.72 (0.21)
LOGISTIC Logistic 2,000 cases v 2,000 controls 4.78 (0.21)
SP1 Logistic 1,000 cases v 2,000 controls 4.70 (0.21)
SP2 Logistic 1,000 cases v 2,000 controls 5.19 (0.22)
HETEROGENEITY Multinomial 2,000 cases v 2,000 controls 5.11 (0.22)
SP1vSP2 Logistic 1,000 cases v 1,000 cases 5.07 (0.21)
MULTINOMIAL: test of association of the causal variant with disease, allowing heterogeneity of allelic odds ratios between sub-phenotypes,
within a multinomial regression framework (2,000 cases against 2,000 controls). LOGISTIC: test of association of the causal variant with disease,
assuming the genetic effect to be the same for both sub-phenotypes, within a logistic regression framework (2,000 cases against 2,000 controls).
SP1: test of association of the causal variant with disease sub-phenotype 1 within a logistic regression framework (1,000 cases against 2,000
controls). SP2: test of association of the causal variant with disease sub-phenotype 2 within a logistic regression framework (1,000 cases against
2,000 controls). HETEROGENEITY: test of heterogeneity of the effect of the causal variant between sub-phenotypes within a multinomial
regression framework (2,000 cases against 2,000 controls). SP1vSP2: test of heterogeneity of the effect of the causal variant between sub-
phenotypes within a logistic regression framework (1,000 cases of sub-phenotype 1 against 1,000 cases of sub-phenotype 2).
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SNP has a fixed heterozygote log-relative risk of disease of
0.1 for sub-phenotype 2 (Fig. 3).
Figure 1 demonstrates that, in the scenario where the effect
of the causal variant is the same for both sub-phenotypes, the
multinomial regression analysis of cases categorized accord-
ing to sub-phenotype is less powerful than conventional
logistic regression analysis of all cases combined, although
the difference is minimal (MULTINOMIAL compared with
LOGISTIC). This is entirely expected since the additional
parameter required to allow for heterogeneity in the multi-
nomial regression model is unnecessary when the effect of
the causal variant is the same for both sub-phenotypes.
Encouragingly, the multinomial regression analysis is more
powerful than logistic regression analysis of cases of each
sub-phenotype, separately, against a shared cohort of
controls (MULTINOMIAL compared with SP1 and SP2). In
this setting, there is a trade-off of the additional parameter
required in the multinomial regression model against the
increased number of cases incorporated in the analysis.
Figure 2 illustrates that, in the scenario where the causal
variant has an effect on only one sub-phenotype, logistic
regression analysis of cases of the specific sub-phenotype
against controls is more powerful than multinomial
regression analysis of cases categorized according to sub-
phenotype, although the difference is minimal (MULTI-
NOMIAL compared with SP1). However, the multinomial
regression model, which allows for heterogeneity of allelic
effects between sub-phenotypes, has noticeably greater
power than logistic regression analysis of all cases
combined (MULTINOMIAL compared with LOGISTIC).
Figure 3 demonstrates that multinomial regression analysis
of cases categorized according to sub-phenotype performs
well, compared with all other approaches, over a wide
range of models in which the causal variant contributes
effects to both sub-phenotypes, but not necessarily in the
same direction (MULTINOMIAL compared with LOGIS-
TIC, SP1 and SP2). Again, these results are expected since
the multinomial regression model has been developed to
allow for heterogeneity of effects between sub-phenotypes.
The power of each of the two tests of heterogeneity is
indistinguishable (HETEROGENEITY compared with
SP1vSP2). Again, this is not unexpected since the controls
do not contribute to our proposed test of heterogeneity
derived within the multinomial regression framework.
Simulations were also performed over a range of MAFs for
the causal variant between 1 and 50%. Although the
absolute power of each test varied dramatically over this
interval, their relative performance remained consistent
with our conclusions for 10% MAF (results not presented).
APPLICATION TO T2D OBESITY SUB-
PHENOTYPES
A total of 4,851 samples from the T2D component of the
main WTCCC experiment [The Wellcome Trust Case
Control Consortium, 2007] passed QC filters: 2,938
controls and 1,924 cases. An additional 11 cases were
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Fig. 1. Power of tests of disease association and heterogeneity of genetic effects between two sub-phenotypes, where the causal variant
(MAF 10%) has the same effect on both sub-phenotypes. Results are presented as a function of the heterozygote log-relative risk at a 5%
significance level. MULTINOMIAL: test of association of the causal variant with disease, allowing heterogeneity of allelic odds ratios
between sub-phenotypes, within a multinomial regression framework (2,000 cases against 2,000 controls). LOGISTIC: test of association
of the causal variant with disease, assuming the genetic effect to be the same for both sub-phenotypes, within a logistic regression
framework (2,000 cases against 2,000 controls). SP1: test of association of the causal variant with disease sub-phenotype 1 within a
logistic regression framework (1,000 cases against 2,000 controls). SP2: test of association of the causal variant with disease sub-
phenotype 2 within a logistic regression framework (1,000 cases against 2,000 controls). HETEROGENEITY: test of heterogeneity of the
effect of the causal variant between sub-phenotypes within a multinomial regression framework (2,000 cases against 2,000 controls).
SP1vSP2: test of heterogeneity of the effect of the causal variant between sub-phenotypes within a logistic regression framework (1,000
cases of sub-phenotype 1 against 1,000 cases of sub-phenotype 2).
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median BMI among case samples is 30.3kgm
 2, leading to
similar frequencies of obese (997) and non-obese (916)
individuals when categorized according to the traditional
obesity threshold (BMI >30). Figure 4 presents Manhattan
plots for 393,143 autosomal SNPs passing QC filters with
MAF >1% across the complete case-control cohort for tests
of association with T2D, and heterogeneity of genetic
effects according to obesity. The multinomial (Fig. 4a) and
logistic (Fig. 4b) regression analyses produce similar
results, in general, highlighting the same regions on
chromosome 10 and 16 with the strongest evidence of
association with T2D. The difference in the magnitude of
signals, for example on chromosome 16, can be explained
by the heterogeneity in allelic odds ratios between obese
and non-obese T2D cases (Fig. 4c).
Table II presents a summary of regions of the genome
demonstrating evidence of association with T2D (Po10
 5)
in a multinomial regression framework, with cases categor-
ized according to obesity. The strongest signal of association
was observed for variants in TCF7L2 (lead SNP rs4506565),
with more convincing evidence obtained from the multi-
nomial regression analysis (P54.0 10
 14) than the logistic
regression analysis of all T2D cases, combined
(P53.0 10
 12). There is clear evidence of heterogeneity
in allelic odds ratios between obesity categories
(P53.0 10
 4). Our results confirm previous findings that
variants in TCF7L2 have stronger effects on non-obese T2D
cases than those that are obese [Cauchi et al., 2006, 2008;
Timpson et al., 2009]. Unsurprisingly, given the association
between variants in FTO and BMI [Frayling et al., 2007],
there is strong evidence of heterogeneity in allelic odds
ratios between obesity categories for SNPs in this gene
(P57.2 10
 7 at rs7193144). As a result, there is evidence of
association with T2D obtained from the multinomial
regression analysis (P59.2 10
 13) is considerably more
convincing than that from the logistic regression analysis of
all cases combined (P52.8 10
 8). Using the simulation
procedure described above, we have estimated the power of
the multinomial and logistic regression-based analyses,
respectively, at a genome-wide significance level of
Po5 10
 7, to be 99.8 and 98.0% for the lead SNP in
TCF7L2, and 99.3 and 77.1% for the lead SNP in FTO.
Unlike previous studies, we have not investigated
association of SNPs with BMI as a quantitative trait in
cases of T2D [Frayling et al., 2007; Timpson et al., 2009]. If
we were to do this, we would be focusing on the
identification of variants contributing effects to obesity
in T2D cases, as opposed to variants contributing effects to
T2D, allowing for the possibility that these effects differ
between obese and non-obese cases. The two tests are thus
assessing the evidence against subtly different null
hypotheses of no association.
Amongst the other signals of association with T2D
identified through application of the multinomial regression
model (Table II), two regions demonstrate clear evidence of
heterogeneity in allelic odds ratios between obese and non-
obese cases: variants close to CAND1 (lead SNP rs11176733,
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Fig. 2. Power of tests of disease association and heterogeneity of genetic effects between two sub-phenotypes, where the causal variant
(MAF 10%) has no effect on sub-phenotype 2. Results are presented as a function of the heterozygote log-relative risk of sub-phenotype
1 at a 5% significance level. MULTINOMIAL: test of association of the causal variant with disease, allowing heterogeneity of allelic
odds ratios between sub-phenotypes, within a multinomial regression framework (2,000 cases against 2,000 controls). LOGISTIC: test of
association of the causal variant with disease, assuming the genetic effect to be the same for both sub-phenotypes, within a logistic
regression framework (2,000 cases against 2,000 controls). SP1: test of association of the causal variant with disease sub-phenotype 1
within a logistic regression framework (1,000 cases against 2,000 controls). SP2: test of association of the causal variant with disease sub-
phenotype 2 within a logistic regression framework (1,000 cases against 2,000 controls). HETEROGENEITY: test of heterogeneity of the
effect of the causal variant between sub-phenotypes within a multinomial regression framework (2,000 cases against 2,000 controls).
SP1vSP2: test of heterogeneity of the effect of the causal variant between sub-phenotypes within a logistic regression framework (1,000
cases of sub-phenotype 1 against 1,000 cases of sub-phenotype 2).
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 6)a n dv a r i a n t si nCCDC33
(lead SNP rs901130, with multinomial P55.5 10
 6).
Previous analysis of the WTCCC T2D cohort, stratified by
obesity, identified a signal of association with variants in
CCDC33 in obese cases only [Timpson et al., 2009], the same
effect as observed in our multinomial regression analysis.
However, on follow in independent samples of UK origin
[Zeggini et al., 2007], the association signal failed to replicate.
More interestingly, the association of variants flanking
CAND1 with T2D has not been previously described. The
association is limited to obese cases, demonstrating a similar
pattern of heterogeneity in allelic odds ratios to those in
FTO, and warrants follow-up in replication cohorts.
DISCUSSION
We have developed a novel test of disease association
with SNPs, allowing for heterogeneity in allelic odds ratios
between sub-phenotypes, within a multinomial regression
framework. This framework is extremely flexible, and can
incorporate covariates to account for non-genetic risk factors
and confounders, such as axes of genetic variation defining
underlying population structure. Although we have pre-
sented results based on a multiplicative disease risk
assumption within each sub-phenotype class, applied to
directly observed genotypes, the multinomial regression
model can easily be extended to incorporate more general
disease models by incorporating dominance, and can be
utilized with imputed data. Within the multinomial regres-
sion framework, we can also perform formal tests of
heterogeneity in allelic odds ratios between sub-phenotypes.
The results of our simulation study highlight two general
conclusions. First, the multinomial regression-based analysis
performs well in comparison to existing methods formu-
lated in a logistic regression framework over a range of
models incorporating heterogeneity of genetic effects
between sub-phenotypes. Second, when genetic effects are
consistent across sub-phenotypes, the loss in power of the
multinomial regression analysis is minimal. Given the
multifarious genetic architecture underlying complex traits,
it is not unreasonable to believe a model of heterogeneity of
effects between sub-phenotypes. It is in this setting that the
advantages of the multinomial regression approach will be
maximized. Our results also highlight, in the context of two
sub-phenotypes, that the multinomial regression-based test
of heterogeneity has equivalent power to a direct compar-
ison of the two case groups via logistic regression. However,
the advantage of the multinomial regression approach is
generalization to more than two sub-phenotypes in a unified
analysis. In a logistic regression context, we would need to
make comparisons between each pair of sub-phenotypes,
making interpretation of heterogeneity statistics more
complex, and would require correction for multiple testing.
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Fig. 3. Power of tests of disease association and heterogeneity of genetic effects between two sub-phenotypes, where the causal variant
(MAF 10%) has a fixed effect on sub-phenotype 2. Results are presented as a function of the heterozygote log-relative risk of sub-
phenotype 1 at a 5% significance level, where the causal variant has a heterozygote log-relative risk of 0.1 for sub-phenotype 2.
MULTINOMIAL: test of association of the causal variant with disease, allowing heterogeneity of allelic odds ratios between sub-
phenotypes, within a multinomial regression framework (2,000 cases against 2,000 controls). LOGISTIC: test of association of the causal
variant with disease, assuming the genetic effect to be the same for both sub-phenotypes, within a logistic regression framework (2,000
cases against 2,000 controls). SP1: test of association of the causal variant with disease sub-phenotype 1 within a logistic regression
framework (1,000 cases against 2,000 controls). SP2: test of association of the causal variant with disease sub-phenotype 2 within a
logistic regression framework (1,000 cases against 2,000 controls). HETEROGENEITY: test of heterogeneity of the effect of the causal
variant between sub-phenotypes within a multinomial regression framework (2,000 cases against 2,000 controls). SP1vSP2: test of
heterogeneity of the effect of the causal variant between sub-phenotypes within a logistic regression framework (1,000 cases of sub-
phenotype 1 against 1,000 cases of sub-phenotype 2).
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method to a GWA study of T2D from the main WTCCC
experiment [The Wellcome Trust Case Control Consortium,
2007], where cases were categorized cases according to
obesity. Given the strong interplay between the two
phenotypes, we expected that multinomial regression analy-
sis might reveal additional T2D associations mediated
through obesity and non-obesity related pathways. Our
analysis provides: (i) stronger signals of association at
established T2D loci than logistic regression-based methods
applied to all cases combined; (ii) confirmation of previous
findings of heterogeneity in genetic effects at TCF7L2 and
FTO according to obesity sub-phenotype in the same samples
[Timpson et al., 2009]; and (iii) evidence of a novel potential
T2D association with variants flanking Cullin-associated and
neddylation-dissociated protein 1 (CAND1) in obese cases
only. CAND1 is a regulatory protein that interferes with the
assembly of the SKP1-CUL1-F-box protein (SCF) ubiquitin
ligase complex and thereby down-regulates ubiquitination of
target proteins, and is involved in ubiquitin-dependent
protein catabolic process. In a meta-analysis of three GWA
studies of T2D [Zeggini et al., 2008], there was no evidence of
Fig. 4. Manhattan plots to summarize results of a GWA study of 1,913 T2D cases and 2,938 controls: (a) multinomial regression analysis
with cases categorized according to obesity sub-phenotypes; (b) logistic regression analysis with all cases combined; and (c)
heterogeneity of effects between obesity sub-phenotypes. Results are presented for 393,143 autosomal SNPs passing QC filters with
MAF > 1% across the complete case-control cohort. The strongest signals of association and heterogeneity (Po10
 5) are indicated in red.
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Genet. Epidemiol.association with SNPs in CAND1 (P50.12). However, the
meta-analysis did not focus on obese cases of T2D, and thus
might not be expected to highlight the association we have
identified through multinomial regression analysis of obesity
sub-phenotypes. As a result, this signal warrants further
follow-up in independent replication samples from the UK or
closely related populations to confirm our findings, ideally
focusing on obese cases of T2D, or by making use of
multinomial regression to allow for heterogeneity of effects
according to BMI.
We have presented the multinomial regression framework
as a powerful approach to the analysis of sub-phenotypes.
However, the utility of this method can be utilized in other
genetic association contexts. For example, we could consider
applying multinomial regression to comparisons of related
phenotypes, such as CD and ulcerative colitis, against a
combined control group. The multinomial regression ap-
proach will have greater power to detect pleiotropic loci,
contributing the same, or different, effects to each phenotype,
than would traditional analysis of each case-control cohort
separately. Furthermore, by combining control cohorts,
providing that they are suitably matched, we may also
increase power to detect loci that contribute effects to just one
phenotype.
The multinomial regression model assumes no ordering in
the disease sub-phenotypes. However, for sub-phenotypes
defined by severity, for example, we may wish to consider
case categories as ordinal. In this setting, we can make use of
the same statistical techniques as described above, but
assume a proportional odds model for disease risk. This
framework requires fewer parameters than the multinomial
regression model, and thus may offer greater power to detect
association if sub-phenotypes can be appropriately ordered.
It is clear that, for many complex traits, it is difficult to
define one unified phenotype with the same underlying
genetic risk factors, and that to do so may, in fact, be
misleading. For example, cases of T2D may be affected as a
result of beta cell failure and/or insulin resistance, and we
might naturally expect that there are different genetic effects
contributing to these two distinct pathways. With larger, and
more clearly refined disease collections, our multinomial
regression approach thus provides a powerful approach to
detect variants contributing to the phenotype overall, whilst
also highlighting those that may be specific to one category
of disease. In this way, we can further our understanding of
the biological mechanisms underlying disease, ultimately
leading to improved, and more targeted therapies.
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